Melodiol Global Health (ASX:ME1DE) COGS-to-Revenue : 0.72 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health COGS-to-Revenue?

Melodiol Global Health's Cost of Goods Sold for the six months ended in Dec. 2023 was A$8.63 Mil. Its Revenue for the six months ended in Dec. 2023 was A$11.93 Mil.

Melodiol Global Health's COGS to Revenue for the six months ended in Dec. 2023 was 0.72.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Melodiol Global Health's Gross Margin % for the six months ended in Dec. 2023 was 27.61%.

Melodiol Global Health COGS-to-Revenue Historical Data

The historical data trend for Melodiol Global Health's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health COGS-to-Revenue Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.41

2.59

1.06

0.97

0.88

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial										0.82	0.81	1.13	1.14	0.72

Melodiol Global Health COGS-to-Revenue Calculation

Melodiol Global Health's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	16.586	/	18.921
	=	0.88

Melodiol Global Health's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8.633	/	11.926
	=	0.72

Melodiol Global Health (ASX:ME1DE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Melodiol Global Health's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	8.633 / 11.926
	=	27.61 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Melodiol Global Health COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (ASX:ME1DE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

COPHF:USA

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines